{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Cisplatin", "Empagliflozin", "Kidney injury", "Nephrotoxicity", "Sodium-glucose transporter 2 Inhibitor (SGLT2I)"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38643451", "DateRevised": {"Year": "2024", "Month": "04", "Day": "21"}, "Article": {"Language": ["eng"], "ELocationID": ["10.1007/s00210-024-03088-6"], "ArticleDate": [{"Year": "2024", "Month": "04", "Day": "21"}], "Journal": {"ISSN": "1432-1912", "JournalIssue": {"PubDate": {"Year": "2024", "Month": "Apr", "Day": "21"}}, "Title": "Naunyn-Schmiedeberg's archives of pharmacology", "ISOAbbreviation": "Naunyn Schmiedebergs Arch Pharmacol"}, "ArticleTitle": "Empagliflozin protective effects against cisplatin-induced acute nephrotoxicity by interfering with oxidative stress and inflammation in Wistar rats.", "Abstract": {"AbstractText": ["Cisplatin (Cis) is a platinum-based antineoplastic drug used in various types of cancers. This drug can induce nephrotoxicity as a cause of acute kidney injury (AKI) by inducing oxidative stress and inflammation. Empagliflozin (Empa) is a newly developed inhibitor of sodium-glucose cotransporter-2 (SGLT2) approved as an antidiabetic medication for patients with type 2 diabetes mellitus. In addition to its blood glucose-lowering effect, Empa has been shown to exert anti-inflammatory and anti-oxidant properties. The current study aimed to investigate the protective effects of Empa on Cis-induced nephrotoxicity in rats. Male Wistar albino rats were divided into five groups, each of six rats: Sham group (received vehicle for 7 days), Control group (received vehicle for 7 days and Cis injection on day 2), Cis\u2009+\u2009Empa10 (received 10mg/kg Empa for 7 days and Cis injection on day 2), Cis\u2009+\u2009Empa30 (received 30mg/kg Empa for 7 days and Cis injection on day 2) and, Empa 30 (received 30mg/kg Empa for 7 days). One day after the last injection in each group, rats were weighed and then sacrificed to analyze the hematological, biochemical, and histological parameters. Cis markedly increased levels of inflammatory parameters such as renal tumor necrosis factor-alpha (TNF-\u03b1), interleukin (IL)-1\u03b2, and myeloperoxidase (MPO) activity. Notably, malondialdehyde (MDA), blood urea nitrogen (BUN), and creatinine levels were enhanced after Cis administration. Also, the chemotherapeutic agent significantly reduced antioxidant indicators such as renal catalase (CAT), glutathione peroxidase (GpX), and superoxide dismutase (SOD). Furthermore, histopathological examinations also revealed severe renal damage following Cis treatment which was improved by Empa administration. Empa treatment at both doses (10 mg/kg and 30 mg/kg) reversed Cis-induced changes in all the above renal parameters. In conclusion, Empa has protective effects on Cis-induced nephrotoxicity by inhibition of oxidative stress and inflammation."], "CopyrightInformation": "\u00a9 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature."}, "AuthorList": [{"Identifier": ["0009-0003-6215-8305"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., P. O. Box: 19419-33111, Tehran, Iran."}, {"Identifier": [], "Affiliation": "GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran."}], "LastName": "Farrokh-Eslamlou", "ForeName": "Nika", "Initials": "N"}, {"Identifier": ["0000-0003-3957-3300"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran."}, {"Identifier": [], "Affiliation": "Department of Toxicology and Pharmacology, School of Pharmacy, and Toxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Momtaz", "ForeName": "Saeideh", "Initials": "S"}, {"Identifier": ["0000-0002-8008-5619"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., P. O. Box: 19419-33111, Tehran, Iran."}, {"Identifier": [], "Affiliation": "GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran."}], "LastName": "Niknejad", "ForeName": "Amirhossein", "Initials": "A"}, {"Identifier": ["0000-0001-6154-5555"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., P. O. Box: 19419-33111, Tehran, Iran."}, {"Identifier": [], "Affiliation": "GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran."}], "LastName": "Hosseini", "ForeName": "Yasamin", "Initials": "Y"}, {"Identifier": ["0009-0001-9261-8195"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Mahdaviani", "ForeName": "Parvin", "Initials": "P"}, {"Identifier": ["0000-0001-5672-9202"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Pharmacy, Urmia University of Medical Sciences, Sero Road, Urmia, 5715799313, Iran. morteza.ghasemnejad@yahoo.com."}], "LastName": "Ghasemnejad-Berenji", "ForeName": "Morteza", "Initials": "M"}, {"Identifier": ["0000-0001-9961-9097"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., P. O. Box: 19419-33111, Tehran, Iran. amirhosein172@hotmail.com."}, {"Identifier": [], "Affiliation": "GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran. amirhosein172@hotmail.com."}], "LastName": "Abdolghaffari", "ForeName": "Amir Hossein", "Initials": "AH"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Naunyn Schmiedebergs Arch Pharmacol", "NlmUniqueID": "0326264", "ISSNLinking": "0028-1298"}}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Abd Elmaaboud MA, Kabel AM, Elrashidy M (2019) Pre-treatment with Empagliflozin ameliorates Cisplatin induced acute kidney injury by suppressing apoptosis. J Appl Biomed 17(1):90", "ArticleIdList": ["10.32725/jab.2019.003", "34907751"]}, {"Citation": "Afkhami Fard L et al (2023) Protective effects of sitagliptin on methotrexate-induced nephrotoxicity in rats. J Environ Sci Health C 41(1\u20132):22\u201335"}, {"Citation": "Ahmed S et al (2022) Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of \u03b1-synuclein and Parkin levels in rotenone-induced Parkinson\u2019s disease in rats. Saudi Pharm J 30(6):863\u2013873", "ArticleIdList": ["10.1016/j.jsps.2022.03.005", "35812142", "9257853"]}, {"Citation": "Bradley PP, Christensen RD, Rothstein G (1982) Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood 60(3):618\u2013622", "ArticleIdList": ["10.1182/blood.V60.3.618.618", "6286012"]}, {"Citation": "Crona DJ et al (2017) A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 22(5):609\u2013619", "ArticleIdList": ["10.1634/theoncologist.2016-0319", "28438887", "5423518"]}, {"Citation": "Domingo IK, Latif A, Bhavsar AP (2022) Pro-inflammatory signalling PRRopels cisplatin-induced toxicity. Int J Mol Sci 23(13):7227", "ArticleIdList": ["10.3390/ijms23137227", "35806229", "9266867"]}, {"Citation": "ElSayed NA et al (2022) 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142023. Diabetes Care 46(Supplement_1):S140\u2013S157", "ArticleIdList": ["10.2337/dc23-S009", "9810476"]}, {"Citation": "G\u00f3mez-Sierra T et al (2018) Role of food-derived antioxidants against cisplatin induced-nephrotoxicity. Food Chem Toxicol 120:230\u2013242", "ArticleIdList": ["10.1016/j.fct.2018.07.018", "29990577"]}, {"Citation": "Gowda S et al (2010) Markers of renal function tests. N Am J Med Sci 2(4):170\u2013173", "ArticleIdList": ["22624135", "3354405"]}, {"Citation": "Hanigan MH, Devarajan P (2003) Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 1:47\u201361", "ArticleIdList": ["18185852", "2180401"]}, {"Citation": "Humanes B et al (2012) Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. Kidney Int 82(6):652\u2013663", "ArticleIdList": ["10.1038/ki.2012.199", "22718191"]}, {"Citation": "Iannantuoni F et al (2019) The SGLT2 Inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes. J Clin Med 8(11)"}, {"Citation": "Jani\u0107 M et al (2022) Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes. J Diabetes Res 2022:6796470", "ArticleIdList": ["10.1155/2022/6796470", "35620570", "9130013"]}, {"Citation": "Jodrell DI et al (1991) The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice. Br J Cancer 64(5):833\u2013838", "ArticleIdList": ["10.1038/bjc.1991.409", "1931603", "1977485"]}, {"Citation": "Kalantari E, Zolbanin NM, Ghasemnejad-Berenji M (2024) Protective effects of empagliflozin on methotrexate induced hepatotoxicity in rats. Biomed Pharmacother 170:115953", "ArticleIdList": ["10.1016/j.biopha.2023.115953", "38064971"]}, {"Citation": "Khezri MR, Varzandeh R, Ghasemnejad-Berenji M (2022) Protective effects of metformin against aluminum phosphide-induced acute hepato-renal damage in rats: an experimental approach. Pestic Biochem Physiol 188:105258", "ArticleIdList": ["10.1016/j.pestbp.2022.105258", "36464363"]}, {"Citation": "Khezri MR, Ghasemnejad-Berenji H, Ghasemnejad-Berenji M (2023) Protective effects of empagliflozin on testicular injury induced by torsion/detorsion in adult male rats. J Pediatr Urol 19(5):545.e1-545.e7", "ArticleIdList": ["10.1016/j.jpurol.2023.06.016", "37394304"]}, {"Citation": "Kilkenny C et al (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8(6):e1000412", "ArticleIdList": ["10.1371/journal.pbio.1000412", "20613859", "2893951"]}, {"Citation": "Lee N et al (2021) Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-\u03baB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways. J Immunol Res 2021:9944880", "ArticleIdList": ["10.1155/2021/9944880", "34124273", "8192181"]}, {"Citation": "Llorens-Cebri\u00e0 C, Molina-Van den Bosch M, Vergara A, Jacobs-Cach\u00e1 C, Soler MJ (2022) Antioxidant Roles of SGLT2 Inhibitors in the Kidney. Biomolecules 12(1):143", "ArticleIdList": ["10.3390/biom12010143", "35053290", "8773577"]}, {"Citation": "Lu YP et al (2022) Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy. Biomed Pharmacother 156:113947", "ArticleIdList": ["10.1016/j.biopha.2022.113947", "36411661"]}, {"Citation": "Miller RP et al (2010) Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2(11):2490\u20132518", "ArticleIdList": ["10.3390/toxins2112490", "22069563"]}, {"Citation": "Mostafa RE, Saleh DO, Mansour DF (2018) Cisplatin-Induced nephrotoxicity in rats: modulatory role of simvastatin and rosuvastatin against apoptosis and inflammation. J Appl Pharm Sci 8(4):043\u2013050"}, {"Citation": "Motie M et al (2017) Effect of weight loss on renal function in overweight and obese patients with heart failure. Diabetes Metab Syndr 11(2):95\u201398", "ArticleIdList": ["10.1016/j.dsx.2016.06.026", "27381968"]}, {"Citation": "Motwani SS, Kaur SS, Kitchlu A (2022) Cisplatin nephrotoxicity: novel insights into mechanisms and preventative strategies. Semin Nephrol 42(6):151341", "ArticleIdList": ["10.1016/j.semnephrol.2023.151341", "37182407"]}, {"Citation": "Nazari-Khanamiri F et al (2023) Biochemical and histopathological evidence for beneficial effects of Empagliflozin pretreatment on acetic acid-induced colitis in rats. BMC Gastroenterol 23(1):332", "ArticleIdList": ["10.1186/s12876-023-02958-2", "37759154", "10523708"]}, {"Citation": "Nematbakhsh M et al (2013) A model for prediction of cisplatin induced nephrotoxicity by kidney weight in experimental rats. J Res Med Sci 18(5):370\u2013373", "ArticleIdList": ["24174938", "3810567"]}, {"Citation": "Prasaja Y, Sutandyo N, Andrajati R (2015) Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia. Asian Pac J Cancer Prev 16(3):1117\u20131122", "ArticleIdList": ["10.7314/APJCP.2015.16.3.1117", "25735341"]}, {"Citation": "Ranasinghe R, Mathai ML, Zulli A (2022) Cisplatin for cancer therapy and overcoming chemoresistance. Heliyon 8(9):e10608", "ArticleIdList": ["10.1016/j.heliyon.2022.e10608", "36158077", "9489975"]}, {"Citation": "Reeves WB (2019) Innate immunity in nephrotoxic acute kidney injury. Trans Am Clin Climatol Assoc 130:33\u201340", "ArticleIdList": ["31516162", "6735994"]}, {"Citation": "Romani AMP (2022) Cisplatin in cancer treatment. Biochem Pharmacol 206:115323", "ArticleIdList": ["10.1016/j.bcp.2022.115323", "36368406"]}, {"Citation": "Santabarbara G et al (2016) Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy. Expert Opin Pharmacother 17(4):561\u2013570", "ArticleIdList": ["10.1517/14656566.2016.1122757", "26581586"]}, {"Citation": "Santos NA et al (2007) Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol 81(7):495\u2013504", "ArticleIdList": ["10.1007/s00204-006-0173-2", "17216432"]}, {"Citation": "Siefker-Radtke AO et al (2022) Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol 23(2):248\u2013258", "ArticleIdList": ["10.1016/S1470-2045(21)00660-4", "35030333"]}, {"Citation": "Ueki M et al (2013) Curcumin ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice. J Biosci Bioeng 115(5):547\u2013551", "ArticleIdList": ["10.1016/j.jbiosc.2012.11.007", "23245727"]}, {"Citation": "Yamada Y et al (2019) Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 4(7):501\u2013510", "ArticleIdList": ["10.1016/S2468-1253(19)30083-4", "31101534"]}, {"Citation": "Yuksel Y et al (2017) Effects of quercetin on methotrexate-induced nephrotoxicity in rats. Hum Exp Toxicol 36(1):51\u201361", "ArticleIdList": ["10.1177/0960327116637414", "27005763"]}, {"Citation": "Zo\u0144 A, Bednarek I (2023) Cisplatin in ovarian cancer treatment-known limitations in therapy force new solutions. Int J Mol Sci 24(8):7585", "ArticleIdList": ["10.3390/ijms24087585", "37108749", "10146189"]}]}], "History": [{"Year": "2024", "Month": "2", "Day": "15"}, {"Year": "2024", "Month": "4", "Day": "7"}, {"Year": "2024", "Month": "4", "Day": "21", "Hour": "12", "Minute": "42"}, {"Year": "2024", "Month": "4", "Day": "21", "Hour": "12", "Minute": "42"}, {"Year": "2024", "Month": "4", "Day": "21", "Hour": "11", "Minute": "4"}], "PublicationStatus": "aheadofprint", "ArticleIdList": ["38643451", "10.1007/s00210-024-03088-6", "10.1007/s00210-024-03088-6"]}}]}